ArticleThe Permanente journal2022

Relapse-Free Course in Nearly Half of Crohn's Disease Patients With Infliximab and Plant-Based Diet as First-Line Therapy: A Single-Group Trial.

Mitsuro Chiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.